Related Experiment Video

Updated: Oct 1, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Evidence based treatment of dyslipidemia associated with diabetes mellitus]

Masato Odawara1

  • 1Department of Endocrinology and Metabolism, Toranomon Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 28, 2002
PubMed

Insights

Diabetic patients face high risks of atherosclerosis and related cardiovascular diseases. Managing blood sugar, cholesterol, blood pressure, and lipids is crucial for preventing these serious macrovascular complications.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Medicine
  • Diabetology

Context:

  • Diabetes mellitus significantly increases atherosclerosis risk.
  • Macrovascular complications like coronary heart disease (CHD), cerebrovascular disease (CVD), and peripheral arterial disease (PAD) are life-threatening in diabetic patients.
  • While glycemic control is important, it is insufficient alone for preventing atherosclerotic diseases.

Purpose:

  • To highlight the critical role of managing dyslipidemia and hypertension in diabetic patients.
  • To emphasize that these conditions, alongside glycemic control, are vital for preventing macrovascular complications.
  • To review evidence supporting lipid-lowering therapy in mitigating cardiovascular risks.

Summary:

  • Diabetic patients are prone to atherosclerosis, leading to severe macrovascular complications.
  • Insulin resistance contributes to dyslipidemia and hypertension in diabetes.
  • Randomized controlled trials demonstrate the benefits of lowering LDL-cholesterol and using statins to prevent CHD and CVD.

Impact:

  • Establishes the multifactorial approach needed for diabetic cardiovascular risk management.
  • Underscores the importance of lipid management beyond glycemic control.
  • Provides evidence for the efficacy of lipid-lowering therapies in preventing major adverse cardiovascular events in diabetes.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...